[Polymyalgia rheumatica: What is the current status?]

Seitz, Michael (2015). [Polymyalgia rheumatica: What is the current status?]. Zeitschrift für Rheumatologie, 74(6), pp. 507-510. Springer-Medizin-Verlag 10.1007/s00393-014-1548-z

[img] Text
art%3A10.1007%2Fs00393-014-1548-z.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (287kB) | Request a copy

The diagnosis of polymyalgia rheumatica (PMR) is based on the typical clinical symptoms and elevated inflammatory markers in blood; however, both are unspecific and the differential diagnosis of the disease still represents a challenge for clinicians. The new consensus classification criteria of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) established in 2012 have a high sensitivity (92.6 %) and specificity (91.2 %) and therefore contribute to improved diagnostics. Glucocorticoids are still the standard treatment with methotrexate and as an alternative and possibly anti-interleukin (anti-IL) 6 therapy in the future.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Seitz, Michael

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0340-1855

Publisher:

Springer-Medizin-Verlag

Language:

German

Submitter:

Stefan Kuchen

Date Deposited:

14 Apr 2016 09:16

Last Modified:

19 Jul 2017 14:12

Publisher DOI:

10.1007/s00393-014-1548-z

PubMed ID:

26169748

Uncontrolled Keywords:

Classification, Joint ultrasonography, Differential diagnoses, Glucocorticoids, Methotrexate

BORIS DOI:

10.7892/boris.80955

URI:

https://boris.unibe.ch/id/eprint/80955

Actions (login required)

Edit item Edit item
Provide Feedback